CAG repeat number governs the development rate of pathology in Huntington's disease

被引:564
作者
Penney, JB
Vonsattel, JP
MacDonald, ME
Gusella, JF
Myers, RH
机构
[1] HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,NEUROPATHOL SERV,BOSTON,MA
[2] HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,NEUROGENET UNIT,BOSTON,MA
[3] BOSTON UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02118
关键词
D O I
10.1002/ana.410410521
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
We compared the number of CAG repeats, the age at death, and the severity of neuropathology in 89 Huntington's disease brains. We found a linear correlation between the CAG repeat number and the quotient of the degree of atrophy in the striatum (the brain region most severely affected in Huntingon's disease) divided by age at death, with an intercept at 35.5 repeats. The largest CAG repeat length, therefore, at which no pathology is expected to develop is 35.5. These results imply that striatal damage in Huntington's disease is almost entirely a linear function of the length of the polyglutamine stretch beyond 35.5 glutamines multiplied by the age of the patient. Thus, it is predicted that the pathological process develops linearly from birth. Analysis of other measures of striatal function could test this hypothesis and might determine when treatment for CAG repeat diseases should start.
引用
收藏
页码:689 / 692
页数:4
相关论文
共 23 条
[1]   Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin [J].
Bao, J ;
Sharp, AH ;
Wagster, MV ;
Becher, M ;
Schilling, G ;
Ross, CA ;
Dawson, VL ;
Dawson, TM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (10) :5037-5042
[2]   Trinucleotide repeat length and clinical progression in Huntington's disease [J].
Brandt, J ;
Bylsma, FW ;
Gross, R ;
Stine, OC ;
Ranen, N ;
Ross, CA .
NEUROLOGY, 1996, 46 (02) :527-531
[3]   Huntington and DRPLA proteins selectively interact with the enzyme GAPDH [J].
Burke, JR ;
Enghild, JJ ;
Martin, ME ;
Jou, YS ;
Myers, RM ;
Roses, AD ;
Vance, JM ;
Strittmatter, WJ .
NATURE MEDICINE, 1996, 2 (03) :347-350
[4]   EVIDENCE OF PRESYMPTOMATIC COGNITIVE DECLINE IN HUNTINGTONS-DISEASE [J].
DIAMOND, R ;
WHITE, RF ;
MYERS, RH ;
MASTROMAURO, C ;
KOROSHETZ, WJ ;
BUTTERS, N ;
ROTHSTEIN, DM ;
MOSS, MB ;
VASTERLING, J .
JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY, 1992, 14 (06) :961-975
[5]   Relationship between trinucleotide repeats and neuropathological changes in Huntington's disease [J].
Furtado, S ;
Suchowersky, O ;
Rewcasle, NB ;
Graham, L ;
Klimek, ML ;
Garber, A .
ANNALS OF NEUROLOGY, 1996, 39 (01) :132-136
[6]   Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract [J].
Goldberg, YP ;
Nicholson, DW ;
Rasper, DM ;
Kalchman, MA ;
Koide, HB ;
Graham, RK ;
Bromm, M ;
KazemiEsfarjani, P ;
Thornberry, NA ;
Vaillancourt, JP ;
Hayden, MR .
NATURE GENETICS, 1996, 13 (04) :442-449
[7]   A COMPARISON OF NEUROLOGICAL, METABOLIC, STRUCTURAL, AND GENETIC EVALUATIONS IN PERSONS AT RISK FOR HUNTINGTONS-DISEASE [J].
GRAFTON, ST ;
MAZZIOTTA, JC ;
PAHL, JJ ;
STGEORGEHYSLOP, P ;
HAINES, JL ;
GUSELLA, J ;
HOFFMAN, JM ;
BAXTER, LR ;
PHELPS, ME .
ANNALS OF NEUROLOGY, 1990, 28 (05) :614-621
[8]   Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familiar amyotrophic lateral sclerosis [J].
Gurney, ME ;
Cutting, FB ;
Zhai, P ;
Doble, A ;
Taylor, CP ;
Andrus, PK ;
Hall, ED .
ANNALS OF NEUROLOGY, 1996, 39 (02) :147-157
[9]   HUNTINGTONS-DISEASE - CAG GENETICS EXPANDS NEUROBIOLOGY [J].
GUSELLA, JF ;
MACDONALD, ME .
CURRENT OPINION IN NEUROBIOLOGY, 1995, 5 (05) :656-662
[10]   THE COMBINED USE OF POSITRON EMISSION TOMOGRAPHY AND DNA POLYMORPHISMS FOR PRECLINICAL DETECTION OF HUNTINGTONS-DISEASE [J].
HAYDEN, MR ;
HEWITT, J ;
STOESSL, AJ ;
CLARK, C ;
AMMANN, W ;
MARTIN, WRW .
NEUROLOGY, 1987, 37 (09) :1441-1447